Yobine by is a Animal medication manufactured, distributed, or labeled by Akorn Animal Health, Inc., Akorn, Inc. Drug facts, warnings, and ingredients follow.
Yobine® contains yohimbine with the chemical name 17 alpha-hydroxy-20 alpha-yohimban-16 beta-carboxylic acid methyl ester. Yohimbine hydrochloride has a molecular weight of 390.89, and the molecular formula is C21H26N2O3HCl. The structural formula is:
Each mL contains: Yohimbine (as the hydrochloride) 2.0 mg, methylparaben 0.9 mg, propylparaben 0.1 mg, citric acid 3.34 mg, and water for injection, pH adjusted with sodium hydroxide.
The safety of yohimbine in pregnant dogs or in dogs intended for breeding has not been established.
Careful consideration should be given before administering to dogs known to be epileptic or seizure prone. The drug reverses the analgesic effects of xylazine as well as the sedative effects. If the animal was given xylazine for its analgesic properties, reversal may result in return of normal pain perception.
Yohimbine is an indolealkylamine alkaloid that acts primarily by blocking central alpha-2 adrenoreceptors that are stimulated by xylazine. Yohimbine is an alpha-2 adrenergic receptor antagonist that easily penetrates the blood-brain barrier. It competitively blocks and antagonizes central nervous system depression or sedation and the bradycardia and respiratory depression caused by xylazine.
Xylazine, an alpha-2 adrenergic agonist with potent sedative, analgesic and muscle relaxant properties, has been used extensively as an analgesic-sedative restraining agent. It has also been used as a preanesthetic agent for many general anesthetics. The central nervous system depressant effect, as well as other pharmacologic effects, is dose dependent.
Yohimbine is useful to counteract the sedation after standard doses of xylazine. The competitive selective blocking of the alpha-2 adrenergic receptor by yohimbine displaces xylazine from these sites and thereby rapidly cancels the effect of the xylazine.
Yohimbine, when used at the prescribed dose, will effectively reverse the effects of xylazine when it is used alone in dogs. Yohimbine abbreviates the anesthesia and chemical restraint of the xylazine.
The reversal of the sedative effects of xylazine by I.V. injection of yohimbine is rapid, usually occurring within one to three minutes, regardless of the route of administration of xylazine.
20 mL multiple-dose vial.
NADA # 140-866, Approved by FDA
AKORN ANIMAL HEALTH
Lake Forest, IL 60045
YO00N Rev. 04/18
Principal Display Panel Text for Container Label:
(yohimbine injection) 2 mg/mL
Xylazine Reversing Agent and
Antidote for Use in Dogs Only
CAUTION: Federal law restricts this drug to use
by or on the order of a licensed veterinarian.
NADA #140-866, Approved by FDA
Principal Display Panel Text for Carton Label:
Xylazine Reversing Agent
and Antidote for Use
in Dogs Only
CAUTION: Federal law restricts
this drug to use by or on the
order of a licensed veterinarian.
Akorn Animal Health Logo
NADA #140-866, Approved by FDA
yohimbine hydrochloride injection, solution
|Labeler - Akorn Animal Health, Inc. (078876357)|
|Akorn, Inc||603980319||MANUFACTURE, ANALYSIS, STERILIZE, PACK, LABEL|